Related Experiment Video

Updated: Jun 17, 2026

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a

Rodger E Tiedemann1, Yuan Xiao Zhu, Jessica Schmidt

  • 1Division of Hematology-Oncology, Mayo Clinic Arizona, 13400 Shea Blvd., Scottsdale, AZ 85259, USA. tiedemann.rodger@mayo.edu

Blood
|December 10, 2009
PubMed

Insights

Researchers identified GRK6 as a selective kinase target in multiple myeloma (MM). Inhibiting GRK6 proved lethal to myeloma cells while sparing normal cells, offering a novel therapeutic strategy for MM.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Validated kinase targets for multiple myeloma (MM) are scarce, hindering kinase inhibitor development.
  • Kinase inhibitors are crucial for cancer treatment strategies.

Purpose of the Study:

  • To identify critically vulnerable kinases in multiple myeloma (MM) cells using a kinome-wide screen.
  • To discover novel therapeutic targets for MM without preconceived notions.

Main Methods:

  • Conducted a kinome-wide small interfering RNA (siRNA) lethality study in MM cell lines with common translocations.
  • Investigated the selective vulnerability and therapeutic potential of GRK6 inhibition in MM.

Main Results:

  • Identified 15 kinases vulnerable in MM cells, including AKT1, AURKA, PLK1, and GRK6.
  • GRK6 inhibition was lethal to 6/7 MM lines but tolerated by normal human cell lines.
  • GRK6 expression is regulated by HSP90 in MM cells; GRK6 silencing reduced STAT3 phosphorylation and MCL1 levels.

Conclusions:

  • GRK6 is selectively vulnerable in MM and its inhibition is cytotoxic.
  • GRK6 inhibition represents a novel, targeted therapeutic strategy for MM.
  • Mice lacking GRK6 are healthy, indicating a favorable safety profile for GRK6 inhibition.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...